Abstract | BACKGROUND AND AIMS: METHODS: Sixty consecutive biopsy proven NASH patients aged 18-70 years with ALT > 1.2 times the upper limit of normal were randomized to receive either pentoxifylline 1200 mg/day in three divided doses orally every day or pioglitazone (30 mg/day) daily for 6 months. All the patients were also instructed to reduce their calorie intake by 500 kcal/day as well as to perform modest exercise (brisk walking) regularly at least 5 days per week. Before and after treatment, liver function tests, serum insulin, C-peptide levels, TNF-α, adiponectin, leptin levels, HOMA-IR and hepatocyte injury and fibrosis scores on liver histology were assessed. RESULTS: CONCLUSIONS:
Pioglitazone shows better improvement in both metabolic factors and liver histology in patients with NASH compared to pentoxifylline.
|
Authors | Barjesh C Sharma, Ajay Kumar, Vishal Garg, Ravi S Reddy, Puja Sakhuja, Shiv K Sarin |
Journal | Journal of clinical and experimental hepatology
(J Clin Exp Hepatol)
Vol. 2
Issue 4
Pg. 333-7
(Dec 2012)
ISSN: 0973-6883 [Print] India |
PMID | 25755455
(Publication Type: Journal Article)
|